Trial Profile
A Randomized, Double Blind (Sponsor Open), Comparative, Multicenter Study to Evaluate the Safety and Efficacy of Subcutaneous Belimumab (GSK1550188) and Intravenous Rituximab Co-administration in Subjects With Primary Sjögren's Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Jun 2022
Price :
$35
*
At a glance
- Drugs Belimumab (Primary) ; Rituximab
- Indications Sjogren's syndrome
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK
- 04 Jun 2022 Results evaluating the efficacy of BEL/RTX and monotherapies using cCRESS overall responses at Weeks (Wks) 24, 52, and 68, and individual item responses at Wk 24, esented at the 23rd Annual Congress of the European League Against Rheumatism
- 09 Nov 2021 Results assessing the changes in minor salivary gland and peripheral blood B cells, presented at the ACR Convergence 2021
- 05 Jun 2021 Results assessing safety and efficacy of subcutaneous Belimumab / intravenous rituximab combination (BEL/RTX) in patients with primary Sjogren's syndrome, presented at the 22nd Annual Congress of the European League Against Rheumatism.